norfloxacin has been researched along with Blood Poisoning in 15 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 9.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 5.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD)." | 1.72 | Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. ( Ahmadi, F; Garg, AX; Kim, RB; Knoll, GA; Muanda, FT; Silverman, MS; Sontrop, JM; Sood, MM; Weir, MA; Yoo, E, 2022) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "Pefloxacin was combined with an aminoglycoside in 13 cases and with rifampicin in 1 case." | 1.27 | [Treatment of septicemia and endocarditis with pefloxacine. 15 cases]. ( Bauchet, J; Pangon, B; Regnier, B; Rouveix, E; Vachon, F; Wolff, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Muanda, FT | 1 |
| Sood, MM | 1 |
| Weir, MA | 1 |
| Sontrop, JM | 1 |
| Ahmadi, F | 1 |
| Yoo, E | 1 |
| Kim, RB | 1 |
| Silverman, MS | 1 |
| Knoll, GA | 1 |
| Garg, AX | 1 |
| Sun, ZL | 1 |
| Sun, SC | 1 |
| He, JM | 1 |
| Lan, JE | 1 |
| Gibbons, S | 1 |
| Mu, Q | 1 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Díaz-De-Alba, P | 1 |
| Docobo-Perez, F | 1 |
| Rodríguez-Martínez, JM | 1 |
| Pascual, Á | 1 |
| Orogade, AA | 1 |
| Akuse, RM | 1 |
| Ghadage, DP | 1 |
| Bal, AM | 1 |
| Brodsky, A | 1 |
| Melero, M | 1 |
| Vay, C | 1 |
| Shah, PM | 1 |
| Classen, DC | 1 |
| Burke, JP | 1 |
| Ford, CD | 1 |
| Evershed, S | 1 |
| Aloia, MR | 1 |
| Wilfahrt, JK | 1 |
| Elliott, JA | 1 |
| Murray, BE | 1 |
| Wolff, M | 1 |
| Pangon, B | 1 |
| Regnier, B | 1 |
| Rouveix, E | 1 |
| Bauchet, J | 1 |
| Vachon, F | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Winston, DJ | 1 |
| Ho, WG | 1 |
| Champlin, RE | 1 |
| Karp, J | 1 |
| Bartlett, J | 1 |
| Finley, RS | 1 |
| Joshi, JH | 1 |
| Talbot, G | 1 |
| Levitt, L | 1 |
| Deresinski, S | 1 |
| Schmeiser, T | 1 |
| Kurrle, E | 1 |
| Arnold, R | 1 |
| Wiesneth, M | 1 |
| Bunjes, D | 1 |
| Hertenstein, B | 1 |
| Kern, W | 1 |
| Heit, W | 1 |
| Heimpel, H | 1 |
| Weinstein, MP | 1 |
| Chomarat, M | 1 |
| Joulie, V | 1 |
| Fournier, G | 1 |
| Bouletreau, P | 1 |
| Flandrois, JP | 1 |
1 review available for norfloxacin and Blood Poisoning
| Article | Year |
|---|---|
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
2 trials available for norfloxacin and Blood Poisoning
| Article | Year |
|---|---|
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Combinations; Drug Therapy, Com | 1987 |
12 other studies available for norfloxacin and Blood Poisoning
| Article | Year |
|---|---|
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Death, Sudden, Cardia | 2022 |
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, | 2020 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Changing patterns in sensitivity of causative organisms of septicaemia in children: the need for quinolones.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Gr | 2004 |
Antibiotic susceptibility pattern of Salmonella worthington isolated from neonates--a retrospective study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Chloramphenicol; Ciprofloxacin; | 2002 |
[Methicillin-resistant Staphylococcus aureus infection in neutropenic patients during norfloxacin prophylaxis].
Topics: Adult; Fatal Outcome; Female; Humans; Immunocompromised Host; Methicillin Resistance; Middle Aged; N | 1992 |
Oral antibiotic prophylaxis in patients with hematological diseases.
Topics: Ciprofloxacin; Humans; Norfloxacin; Sepsis; Staphylococcal Infections | 1991 |
Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Drug Re | 1990 |
[Treatment of septicemia and endocarditis with pefloxacine. 15 cases].
Topics: Adult; Aged; Anti-Infective Agents; Child; Drug Resistance, Microbial; Endocarditis, Bacterial; Fema | 1986 |
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Female; Human | 1988 |
Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.
Topics: Anti-Bacterial Agents; Bacteria; Cefotaxime; Ceftazidime; Enoxacin; Fluoroquinolones; Humans; Imipen | 1988 |
[Pharmacokinetic study of pefloxacin in 37 hospital patients under resuscitation].
Topics: Humans; Intensive Care Units; Kinetics; Meningitis; Norfloxacin; Pefloxacin; Pneumonia; Risk; Sepsis | 1985 |